Jaundice and intrahepatic cholestasis following high-dose megestrol acetate for breast cancer.
High-dose megestrol acetate, a synthetic progestin, has been advocated recently in treating patients with metastatic breast carcinoma; no significant increase in adverse effects has been reported. This report describes a patient with jaundice and intrahepatic cholestasis after high-dose megestrol acetate therapy. This cholestatic lesion may have a pathogenesis similar to that observed with estrogens and oral contraceptives.
Foitl
D R
DR
Department of Pathology, Columbia University College of Physicians and Surgeons, NY 10032.
Hyman
G
G
Lefkowitch
J H
JH
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols; D001663:Bilirubin / Q000097:blood; D001943:Breast Neoplasms / Q000188:drug therapy*; D002780:Cholestasis, Intrahepatic / Q000139:chemically induced*; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007565:Jaundice / Q000139:chemically induced*; D015409:Mastectomy, Radical; D008535:Megestrol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D019290:Megestrol Acetate; D008727:Methotrexate / Q000008:administration & dosage; D011241:Prednisone / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D014750:Vincristine; D003520:Cyclophosphamide; D008535:Megestrol; D001663:Bilirubin; D019290:Megestrol Acetate; D005472:Fluorouracil; D011241:Prednisone; D008727:Methotrexate